The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy ofEGFR-TKIs in patients with advanced-stage NSCLC [corrected]
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
25202114
PII: 34/9/5193
Knihovny.cz E-resources
- Keywords
- EGFR-TKI, NSCLC, NSE, Predictive biomarkers, TK,
- MeSH
- Adult MeSH
- ErbB Receptors antagonists & inhibitors MeSH
- Phosphopyruvate Hydratase metabolism MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Lung Neoplasms drug therapy enzymology mortality pathology MeSH
- Carcinoma, Non-Small-Cell Lung drug therapy enzymology mortality pathology MeSH
- Prognosis MeSH
- Antineoplastic Agents therapeutic use MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Thymidine Kinase metabolism MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- ErbB Receptors MeSH
- Phosphopyruvate Hydratase MeSH
- Protein Kinase Inhibitors MeSH
- Antineoplastic Agents MeSH
- Thymidine Kinase MeSH
BACKGROUND/AIM: Tumor biomarkers are used for diagnostics and follow-up monitoring of patients with non-small cell lung cancer (NSCLC). We focused on the predictive role of neuron-specific enolase (NSE) and thymidine [corrected] kinase (TK) in patients with advanced-stage NSCLC treated with epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs). PATIENTS AND METHODS: In a total of 163 patients with advanced-stage (IIIB or IV) NSCLC treated with EGFR-TKIs (erlotinib or gefitinib), pre-treatment levels of NSE and TK were measured. RESULTS: We observed significantly shorter progression-free (PFS) and overall survival (OS) in patients with high NSE levels (p=0.002; p=0.003) and also in those with high TK levels (p=0.026; p=0.020). The multivariate Cox proportional hazards model confirmed that high NSE is a strong independent predictive factor for short PFS (hazard ratio; HR=2.36; p=0.003). CONCLUSION: High pre-treatment serum levels of NSE is an independent biomarker predicting poor outcome of patients with NSCLC treated with EGFR-TKIs.
